Quantcast
Last updated on April 17, 2014 at 12:01 EDT

Latest ondansetron Stories

2010-05-06 07:30:00

BOTHELL, Wash., May 6 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE AMEX: DDD) today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation, (RedHill), granting RedHill the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's proprietary extended delivery technology (CDT). Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and...

2009-08-04 12:52:00

SCHAUMBURG, Ill., Aug. 4 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ondansetron in 5% dextrose injection in premix bags, an antiemetic and selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy. Sagent's ondansetron in 5% dextrose injection in premix bags is the generic equivalent of GlaxoSmithKline's ZOFRAN(R) Injection Premixed. Sagent will begin marketing...

2009-06-10 07:01:00

WARREN, N.J., June 10 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today that the new drug application (NDA) for ondansetron orally dissolving film strip (ODFS) has been accepted for review by the U.S. Food and Drug Administration (FDA). Ondansetron ODFS was developed using MonoSol Rx's proprietary PharmFilm(R) technology to deliver the anti-emetic therapy ondansetron...

2009-06-10 07:00:00

WOODCLIFF LAKE, N.J., June 10 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and...

2009-05-21 08:00:00

Safety and Efficacy Study of Zolpidem Tartrate Sublingual Tablet in Treating Middle-of-the-Night Awakening on an As-Needed Basis Evaluation of Ondansetron Augmentation in the Treatment of Obsessive Compulsive Disorder RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience,...

2009-05-15 11:27:51

Household ginger and a new drug called casopitant mesylate can reduce the nausea and vomiting caused by chemotherapy, U.S. researchers said. Adding about a half-teaspoon of ground ginger to food in the days before and after chemotherapy reduced grueling side effects for many of the 644 patients in a large, random, clinical study, said Julie L. Ryan, lead author of the study at the University of Rochester Medical Center. Ginger has a potent anti-inflammatory effect in the gut, Ryan told the...

2009-05-14 09:44:22

Adding a third drug to a popular chemotherapy regimen can help reduce the nausea and vomiting that many patients experience.Researchers from the University of Vermont in Burlington, VT, studied 810 patients from 77 centers in 22 countries. The participants took the chemo regimen of dexamthesone and ondansetron. This is a treatment used for patients with many types of solid tumors including colorectal and pancreatic cancers. Some of the patients received a third drug -- casopitant mesylate...

2009-04-09 07:11:00

WARREN, N.J., April 9 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced the submission on April 7, 2009 of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the orally dissolving film strip (ODFS) formulation of ondansetron....

2009-04-09 07:00:00

Files NDA for Ondansetron Orally Dissolving Film Strip BioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF LAKE, N.J., April 9 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today provides an update on two of its pipeline products. Ondansetron Orally Dissolving Film Strip On April 7, 2009, Strativa submitted a New Drug Application (NDA) for its new orally dissolving film...

2009-03-20 06:00:00

ZURICH, Switzerland, March 20 /PRNewswire/ -- A new, innovative study shows that a single dose of palonosetron, the second generation 5-HT3 antagonist, plus dexamethasone not only prevents chemotherapy-induced nausea and vomiting (CINV), but also allows adequate caloric intake in oncology patients. Data presented today at the ESMO Symposium on Cancer and Nutrition in Zurich, Switzerland New data presented today at the ESMO (European Society of Medical Oncology) Symposium on Cancer...